Shuangjia Wang

Dr. Shuangjia Wang


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Oncology Reports
Verified
Journal Article
Closed access
PDF file
DCDong-Han Chen
Dong-Han Chen
QWQiu-Wan Wu
Qiu-Wan Wu
XLXiu-Dong Li
Xiu-Dong Li
SWShuangjia Wang
Shuangjia Wang
ZZZhi-Ming Zhang
Zhi-Ming Zhang
Hepatocellular carcinoma (HCC) is the second leading cause of cancer mortality worldwide, which is mainly due to relapse and metastasis. Synaptophysin-like 1 (SYPL1), a member of SYP family proteins, exerts complicated functions, which prompted us to wonder whether SYPL1 contributed to HCC progress. Herein, we performed integrative experiments of quantitative real-time polymerase chain reaction (qRT-PCR), western blot analysis and immunohistochemistry (IHC), and found that SYPL1 overexpression in HCC tissues was closely correlated with several malignant clinicopathologic features of HCC. The results from IHC in serial sections of HCC tissues further indicated that SYPL1 expression was associated with epithelial-mesenchymal transition (EMT) biomarkers of HCC cells. Additionally, Kaplan-Meier survival analysis showed that SYPL1 overexpression was significantly associated with reduced overall survival (OS) (p<0.001) and disease-free survival (DFS) (p=0.002). Furthermore, univariate and multivariate Cox proportional hazards analysis identified SYPL1 as an independent prognostic factor for OS [hazard ratio (HR), 2.443, 95% confidence interval (CI), 1.429-4.177, p=0.001] and DFS (HR, 1.680, 95% CI=1.012-2.788, p=0.045) of HCC patients. Collectively, SYPL1 overexpression predicts poor prognosis of HCC and may associate with EMT of HCC cells. Therefore, SYPL1 could serve as a future novel biomarker and potential therapy target for HCC.

1 January 2021 in Journal of Cancer
Verified
Journal Article
Open access
SWShuangjia Wang
Shuangjia Wang
XLXiu-Dong Li
Xiu-Dong Li
LWLu-Peng Wu
Lu-Peng Wu
PGPing Guo
Ping Guo
LFLiu-Xing Feng
Liu-Xing Feng
BLBin Li
Bin Li
Purpose: Various studies have identified miR-202 critically participated in the development of different cancers. However, the potential mechanisms underlying the carcinogenesis of pancreatic cancer (PC) still remains elusive.

13 June 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
LFLiuXing Feng
LiuXing Feng
QYQuan Yuan
Quan Yuan
HYHao Yu
Hao Yu
RYRongjie Ye
Rongjie Ye
ZXZhenHao Xie
ZhenHao Xie
SWShuangjia Wang
Shuangjia Wang
Intrahepatic cholangiocarcinoma (iCCA) represents a growing health concern due to its increasing incidence and poor prognosis, highlighting the urgent need for biomarkers and therapeutic targets. This study utilized BayesPrism deconvolution, Weighted Gene Co-expression Network Analysis (WGCNA), and Summary Mendelian Randomization (SMR), integrated with single-cell RNA sequencing (scRNA-seq) data, to analyze the tumor microenvironment. Seven distinct cell subpopulations, including Exhausted CD8 + T cells (Tex), were identified. Notably, scPagwas analysis revealed gene enrichment in UQCRH, HINT1, and AKR1C3, associated with Tex. BayesPrism analysis confirmed their increased presence in the tumor microenvironment, indicating a role in immune evasion. WGCNA identified 594 genes linked to these cells, with PNO1 and AKR1C5P emerging as potential disease-associated genes. These findings highlight the critical role of Tex in immune suppression and identify key genes for further investigation in iCCA progression and treatment strategies.

6 August 2025 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
HYHao Yu
Hao Yu
QYQuan Yuan
Quan Yuan
RYRui Yu
Rui Yu
RYRongjie Ye
Rongjie Ye
SYShuqi Yang
Shuqi Yang
CZChao Zhan
Chao Zhan
Background Neoadjuvant therapy (NAT) is a promising strategy to improve long-term outcomes in hepatocellular carcinoma (HCC), particularly for patients with borderline resectable. Targeted therapy, transarterial chemoembolization (TACE), immunotherapy, and radiotherapy are all effective NAT strategies for HCC; however, the optimal NAT regimen for HCC remains undefined. Methods This multicentre retrospective study included 64 HCC patients who underwent NAT followed by surgical resection between 2020 and 2024 at four tertiary hospitals in China. Based on the treatment regimen, patients were divided into two groups: the dual-therapy group, which received TACE combined with either lenvatinib or bevacizumab, and the triple-therapy group, which additionally received anti-PD-1/PD-L1 immunotherapy. Survival outcomes and prognostic factors were evaluated using the Kaplan–Meier method and Cox proportional hazards models. Results The triple-therapy group demonstrated significantly better progression-free survival (PFS) and overall survival (OS) compared to the dual-therapy group (PFS: HR = 0.450, P = 0.048; OS: HR = 0.437, P = 0.039). Multivariate Cox analysis identified triple therapy, lower tumour burden, and higher pathological response as favourable prognostic factors, whereas vascular invasion and elevated alpha-fetoprotein (AFP) levels were linked to poorer outcomes. Additionally, in this Chinese HCC cohort, the China Liver Cancer (CNLC) staging system appeared to provide superior prognostic stratification compared to the Barcelona Clinic Liver Cancer (BCLC) system. Conclusion In the context of NAT for HCC, triple therapy—combining TACE, targeted agents, and immunotherapy—appears to be a more effective treatment option compared to dual therapy.

1 July 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
HYHao Yu
Hao Yu
QYQuan Yuan
Quan Yuan
LFLiu-Xing Feng
Liu-Xing Feng
JXJia-Huan Xu
Jia-Huan Xu
SZShen-Yuan Zhan
Shen-Yuan Zhan
SWShuangjia Wang
Shuangjia Wang
Pancreatic cancer (PC), often referred to as the “king of cancers”, has demonstrated limited success with immunotherapies, many of which are still under development. Psoriasis, a common hereditary skin disorder involving genetic, immune, and environmental factors, is only partially understood and has been linked to an elevated risk of various cancers, including PC. However, the precise mechanisms through which psoriasis may influence PC progression remain unclear. A comparative analysis of the immune microenvironments in both diseases revealed that tertiary lymphoid structures (TLS) are downregulated in both conditions. Gene expression profiles from public databases were analyzed, and TLS-associated genes were subjected to Cox regression and Kaplan-Meier analyses. Machine learning algorithms identified GBP2 as a risk factor and ZNF814 as a protective factor. The TLS pathway was underexpressed in PC, and GBP2, PARP9, ESRP1, FERMT1, and ZNF814 were identified as critical determinants of survival outcomes. GBP2 was linked to poor prognosis, while ZNF814 was associated with favorable outcomes. Clinical risk plots, ROC curves, and Kaplan-Meier analyses were used to assess model performance. Additionally, qPCR experiments validated the expression of these genes in pancreatic cancer cell lines. These results offer valuable insights into PC progression, providing a foundation for improved clinical management and future research.